0Effects of the COVID-19 Pandemic on Treatment Adherence in Patients with Chronic Heart Failure

Overview

Journal Caspian J Intern Med

Specialty General Medicine

Date 2022 Jul 25

PMID 35872693

Authors

Sergey Yu Martsevich

Yulia V Lukina

Natalia P Kutishenko

Elmira T Guseynova

Affiliations

Soon will be listed here.

Abstract

Background: To assess the influence of the COVID-19 (Coronavirus Disease 2019 pandemic on treatment adherence by patients with CHF (Chronic heart failure) and to determine the factors associated with changing adherence during home-isolation.

Methods: The survey was conducted in patients participating in the COMPLIANCE study (ClinicalTrials.gov. NCT04262583). Thirty-one patients, included into in the COMPLIANCE study before March 1, 2020, were interviewed through phone calls. A modified adherence scale of the National Society for Evidence-Based Pharmacotherapy was used, which permits to assess of overall adherence, adherence to particular drugs and the main causes for non-adherence.

Results: In the whole group of patients, only a tendency to reduced overall adherence was registered during the COVID-19 pandemic (р=0,256). Significant differences in the rate of adherence deterioration were revealed for angiotensin-converting enzyme (ACE) inhibitors (p=0.031) and for statins (p=0.002). The reasons for non-adherence were lack of opportunity to contact with a physician, inability to perform investigations necessary for correcting prescribed pharmacotherapy, and side effects.

Conclusion: A tendency to deterioration of adherence to prescribed pharmacotherapy was revealed during the COVID-19 pandemic. A significant decline in adherence was registered to ACE inhibitors and statins.

Citing Articles

A Systematic Review Uncovering Modifiable Influences on Statin Adherence.

Rosenberg J, Lampridou S, Moores A, Garfield S, Wingfield D, Judah G Patient Prefer Adherence. 2025; 19():29-48.

PMID: 39780938 PMC: 11708203. DOI: 10.2147/PPA.S502645.

Correlation between coronary artery calcification and COVID-19.

Abrotan S, Jalali S, Hedayati-Godarzi M, Jafaripour I, Saravi M, Ziaie N Caspian J Intern Med. 2024; 15(3):466-471.

PMID: 39011441 PMC: 11246690. DOI: 10.22088/cjim.15.3.466.

Coronary artery calcification score as a prognostic indicator for COVID-19 mortality: evidence from a retrospective cohort study in Iran.

Hedayati Goudarzi M, Abrotan S, Ziaie N, Amin K, Saravi M, Jalali S Ann Med Surg (Lond). 2024; 86(6):3227-3232.

PMID: 38846865 PMC: 11152861. DOI: 10.1097/MS9.0000000000001661.

Influence of COVID-19 on treatment adherence and psychological well-being in a sample of hypertensive patients: a cross-sectional study.

Gomez-Escalonilla Lorenzo S, Martinez I, Notario Pacheco B BMC Psychiatry. 2023; 23(1):121.

PMID: 36823568 PMC: 9947937. DOI: 10.1186/s12888-022-04473-2.

References

Hill E . Understanding when to use the new patient E/M codes. Fam Pract Manag. 2003; 10(8):33-6. View

Zheng S, Yang L, Zhou P, Li H, Liu F, Zhao R . Recommendations and guidance for providing pharmaceutical care services during COVID-19 pandemic: A China perspective. Res Social Adm Pharm. 2020; 17(1):1819-1824. PMC: 7102520. DOI: 10.1016/j.sapharm.2020.03.012. View

Kuster G, Pfister O, Burkard T, Zhou Q, Twerenbold R, Haaf P . SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19?. Eur Heart J. 2020; 41(19):1801-1803. PMC: 7184407. DOI: 10.1093/eurheartj/ehaa235. View

Kostev K, Kumar S, Konrad M, Bohlken J . Prescription rates of cardiovascular and diabetes therapies prior to and during the COVID-19 lockdown in Germany. Int J Clin Pharmacol Ther. 2020; 58(9):475-481. DOI: 10.5414/CP203849. View

Driggin E, Madhavan M, Bikdeli B, Chuich T, Laracy J, Biondi-Zoccai G . Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic. J Am Coll Cardiol. 2020; 75(18):2352-2371. PMC: 7198856. DOI: 10.1016/j.jacc.2020.03.031. View

Fragoulis G, Evangelatos G, Arida A, Bournia V, Fragiadaki K, Karamanakos A . Treatment adherence of patients with systemic rheumatic diseases in COVID-19 pandemic. Ann Rheum Dis. 2020; 80(4):e60. DOI: 10.1136/annrheumdis-2020-217935. View

Barberio B, Zingone F, Bertani L, Savarino E . The Adherence to Infusible Biologic Therapies in Inflammatory Bowel Disease Patients during the COVID-19 Pandemic: Is It Really a Problem?. Gastroenterology. 2020; 160(5):1903-1904. PMC: 7367016. DOI: 10.1053/j.gastro.2020.07.017. View

Viana M, Laszczynska O, Mendes S, Frioes F, Lourenco P, Bettencourt P . Medication adherence to specific drug classes in chronic heart failure. J Manag Care Spec Pharm. 2014; 20(10):1018-26. PMC: 10441014. DOI: 10.18553/jmcp.2014.20.10.1018. View

Vakirlis E, Bakirtzi K, Papadimitriou I, Vrani F, Sideris N, Lallas A . Treatment adherence in psoriatic patients during COVID-19 pandemic: Real-world data from a tertiary hospital in Greece. J Eur Acad Dermatol Venereol. 2020; 34(11):e673-e675. PMC: 7323240. DOI: 10.1111/jdv.16759. View

10.

de Joode K, Dumoulin D, Engelen V, Bloemendal H, Verheij M, van Laarhoven H . Impact of the coronavirus disease 2019 pandemic on cancer treatment: the patients' perspective. Eur J Cancer. 2020; 136:132-139. PMC: 7334940. DOI: 10.1016/j.ejca.2020.06.019. View

11.

Kaye L, Theye B, Smeenk I, Gondalia R, Barrett M, Stempel D . Changes in medication adherence among patients with asthma and COPD during the COVID-19 pandemic. J Allergy Clin Immunol Pract. 2020; 8(7):2384-2385. PMC: 7194036. DOI: 10.1016/j.jaip.2020.04.053. View

12.

Khan N, Patel D, Xie D, Pernes T, Lewis J, Yang Y . Adherence of Infusible Biologics During the Time of COVID-19 Among Patients With Inflammatory Bowel Disease: A Nationwide Veterans Affairs Cohort Study. Gastroenterology. 2020; 159(4):1592-1594.e1. PMC: 7305703. DOI: 10.1053/j.gastro.2020.06.044. View

13.

de Vries S, Keers J, Visser R, de Zeeuw D, Haaijer-Ruskamp F, Voorham J . Medication beliefs, treatment complexity, and non-adherence to different drug classes in patients with type 2 diabetes. J Psychosom Res. 2014; 76(2):134-8. DOI: 10.1016/j.jpsychores.2013.11.003. View